Akoya Biosciences, Inc. announced its financial results for the fourth quarter and full year ending December 31, 2024, on March 17, 2025. The company reported a net loss of $8.2 million for the fourth quarter.
Despite a challenging 2024 in the life science tools market, Akoya highlighted several operational achievements. These included strengthening gross margins, reducing operating expenses, and advancing its companion diagnostics programs throughout the year. The company's installed base expanded to 1,330 instruments.
Akoya also noted the launch of its Manufacturing Center of Excellence, the expansion of its content menu into new markets like neurobiology, and continued advancement of clinical partnerships with Acrivon and NeraCare. Due to the pending acquisition by Quanterix Corporation, Akoya did not host an earnings conference call or provide forward guidance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.